LPL Financial LLC increased its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 113.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,317 shares of the company's stock after purchasing an additional 8,671 shares during the period. LPL Financial LLC's holdings in argenx were worth $10,035,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. Stifel Financial Corp raised its stake in shares of argenx by 15.3% during the third quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock valued at $4,788,000 after purchasing an additional 1,170 shares during the period. Stephens Inc. AR purchased a new stake in argenx during the 4th quarter worth $310,000. Ritholtz Wealth Management increased its stake in argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after buying an additional 414 shares during the period. Jones Financial Companies Lllp lifted its holdings in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares in the last quarter. Finally, MML Investors Services LLC boosted its position in argenx by 16.9% in the 3rd quarter. MML Investors Services LLC now owns 8,699 shares of the company's stock valued at $4,715,000 after buying an additional 1,255 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.
argenx Price Performance
Shares of ARGX stock traded up $15.20 during trading hours on Wednesday, reaching $564.13. The stock had a trading volume of 893,956 shares, compared to its average volume of 303,169. The firm has a market capitalization of $34.28 billion, a PE ratio of -641.06 and a beta of 0.60. The firm has a 50-day simple moving average of $611.51 and a 200-day simple moving average of $603.50. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21.
argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities analysts anticipate that argenx SE will post 3.13 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms recently commented on ARGX. Citigroup reiterated an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Sanford C. Bernstein raised argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Piper Sandler increased their target price on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research note on Tuesday, January 7th. Truist Financial restated a "buy" rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, Wells Fargo & Company increased their price objective on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $687.00.
Read Our Latest Analysis on ARGX
About argenx
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Recommended Stories
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
